5–7 Dec 2018
CERN
Europe/Zurich timezone

Study of the kinetics of complex formation and in vivo stability of novel radiometal-chelate conjugates for applications in nuclear medicine.

5 Dec 2018, 17:30
2h
61/1-201 - Pas perdus - Not a meeting room - (CERN)

61/1-201 - Pas perdus - Not a meeting room -

CERN

10
Show room on map

Speaker

Valery Radchenko (TRIUMF)

Description

Targeted Radionuclide Therapy (TRT) and diagnostics are currently the most intensively developing fields of nuclear medicine as they allow the very precise imaging of tumors (or other targeted tissues), and the minimization of healthy tissue damage during medical therapy. TRT relies on the labeling of a radionuclide to a targeting vector – a biomolecule that has a high affinity to over-expressed antigens on the surface of tumor cells. It targets tumors, or other diseases, at the cellular level and increases the radiation dose delivered to the target tissue relative to the healthy tissue during therapy. However, the design and synthesis of radiopharmaceuticals suitable for TRT require a solid understanding of the stability of radionuclide complexes in vivo. Conventional methods to characterize the thermodynamic stability of complexes often rely on non-radioactive surrogates under biologically irrelevant conditions; moreover, little information on the kinetics of formation and the kinetic inertness can be drawn. Over the past two years (2017-2018) we received multiple radioactive beams to study the complexation behaviour and preference of various radiometals with the use of Perturbed Angular Correlation of γ-rays (PAC) spectroscopy.
In August 2017, our team partook in a beam of Cd-111 at ISOLDE for chelation studies with various systems and comparisons with previous results obtained with In-111 (mother isotope). Later in September we probed beams of radiolanthanides (Nd-139, La-140, Gd-147, Gd-149 and Lu-172), some of which were produced for the first time, in order to test the complexation preference, the complex structures as well as several novel chelators synthesized by our collaborators at UBC Chemistry.
Furthermore, in September of 2018 our team tested the chelation of Hg-199 with the common chelators DOTA and EDTA. Later in October, the ISOLDE team made available for the first time a beam of Sb-118 and its first PAC spectra was measured.
All of the above stated results will be presented and further possible experiments and directions will be discussed for this project.

Authors

Valery Radchenko (TRIUMF) Monika Stachura (TRIUMF (CA)) Dr Caterina Ramogida (TRIUMF) Dr Cornelia Hoehr (TRIUMF) Dr Paul Schaffer (TRIUMF) Prof. Chris Orvig (Department of Chemistry, University of British Columbia) Una Jermilova (TRIUMF/Department of Chemistry, University of British Columbia) Dr Dmitry Filosofov (Joint Institute for Nuclear Research (JINR)) Elena Kurakina (Joint Instittue for Nuclear Research (JINR)) Prof. Lars Hemmingsen (University of Copenhagen (DK)) Prof. Peter Thulstrup (Department of Chemistry, University of Copenhagen) Morten Bjerrum (Department of Chemistry, University of Copenhagen) Dr Ulli Koester (Institut Laue-Langevin (FR)) Karl Johnston (CERN) Dr Joao Guilherme Correia (CERN) Juliana Schell (Institut Fur Materialwissenschaft Universität Duisburg-Essen (D) Prof. Doru Lupascul (Institute for Materials Science and Center for Nanointegration, Duisburg-Essen (CENIDE), University of Duisburg-Essen )

Presentation materials

There are no materials yet.